NYSE American - Delayed Quote • USD
Can-Fite BioPharma Ltd. (CANF)
At close: April 18 at 3:59 PM EDT
Pre-Market: 5:13 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -0.4 | -0.41 | -1.09 | -1.02 |
| Low Estimate | -0.4 | -0.41 | -1.65 | -1.75 |
| High Estimate | -0.4 | -0.41 | -0.54 | -0.3 |
| Year Ago EPS | -0.65 | -0.42 | -3 | -1.09 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | 400k | 2.88M |
| Low Estimate | -- | -- | -- | 800k |
| High Estimate | -- | -- | 800k | 4.95M |
| Year Ago Sales | 196k | 196k | 743k | 400k |
| Sales Growth (year/est) | -- | -- | -46.20% | 620.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.52 | -0.42 | -0.44 | -0.26 |
| EPS Actual | -0.65 | -0.42 | -0.44 | -1.49 |
| Difference | 0.87 | 0 | 0 | -1.23 |
| Surprise % | 57.20% | 0.00% | 0.00% | -473.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.41 | -1.09 | -1.02 |
| 7 Days Ago | -0.4 | -0.41 | -1.09 | -1.02 |
| 30 Days Ago | 0 | 0 | -0.28 | -0.3 |
| 60 Days Ago | 0 | 0 | -0.28 | -0.3 |
| 90 Days Ago | 0 | 0 | -0.54 | -0.3 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CANF | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 38.50% | -- | -- | 0.80% |
| Next Qtr. | 2.40% | -- | -- | 9.60% |
| Current Year | 63.70% | -- | -- | 4.50% |
| Next Year | 6.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/24/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 6/2/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/13/2023 |
Related Tickers
PPBT Purple Biotech Ltd
0.4610
+2.67%
XTLB XTL Biopharmaceuticals Ltd.
2.4400
-1.21%
EVGN Evogene Ltd.
0.6408
-6.45%
BLRX BioLineRx Ltd.
0.6401
+2.88%
BONS.TA Bonus BioGroup Ltd.
16.30
0.00%
PLUR Pluri Inc.
5.05
-2.32%
ENLV Enlivex Therapeutics Ltd.
1.4000
-5.41%
IMNN Imunon, Inc.
1.1250
-1.32%
ORMP Oramed Pharmaceuticals Inc.
2.2000
-5.58%
PLX Protalix BioTherapeutics, Inc.
1.1300
-1.74%